Latest GPC Biotech Stories

2009-06-03 07:00:00

LONG BRANCH, N.J., June 3 /PRNewswire/ -- The 2009 Pharma ChemOutsourcing Conference & Exhibition attendance is way up again in 2009 and is poised to shatter the attendance record set in 2008. The remarkable success of last year's meeting generated the positive buzz responsible for much of the growth. Attendance for the September 14-16, 2009 event is expected to be about 1000. Also attracting high attendance is the conference program newly focused on the outsourcing needs of small...

2008-10-30 06:00:44

GPC Biotech has reported preclinical data on RGB-286638, the company's multi-targeted protein kinase inhibitor, that supported the potential utility of RGB-286638 against some hematological malignancies. The data demonstrated that the RGB-286638 small molecule has potent activity against chronic myeloid leukemia (CML) in in vivo models that are resistant to imatinib (Gleevec) and to dasatinib (Sprycel), the current standards of care for treating this form of cancer. Additionally,...

2008-10-27 06:00:23

GPC Biotech AG (Frankfurt Stock Exchange: GPC, NASDAQ: GPCB) today reported that pre-clinical data on RGB-286638, the Company's multi-targeted protein kinase inhibitor, were presented at the 20th EORTC-NCI-AACR Symposium: Molecular Targets and Cancer Therapeutics in Geneva, Switzerland in a poster entitled, "RGB-286638 is a novel multi-targeted protein kinase inhibitor with activity in chronic myelogenous leukemia (CML) models," (Abstract #578). The data presented demonstrate that the...

2008-07-28 12:01:07

GPC Biotech has reported that the company has been informed by its partner for satraplatin in Europe that they plan to withdraw the marketing authorization application for satraplatin plus prednisone for the treatment of hormone-refractory prostate cancer patients whose prior chemotherapy has failed. This decision was based on a list of outstanding issues received following review by the Committee for Medicinal Products for Human Use of the European Medicines Agency of the filing, which...

2008-06-25 06:03:22

GPC Biotech has initiated a Phase II study evaluating satraplatin in combination with the steroid, prednisone, in patients with metastatic hormone-refractory prostate cancer who previously have been treated with docetaxel. The study is being sponsored by the US National Cancer Institute. The trial is a single-arm study with a planned enrollment of 66 patients with metastatic hormone-refractory prostate cancer who have been previously treated with docetaxel therapy and with no more than one...

2008-06-25 00:02:49

Study seeks to determine if presence of certain gene impacts patient outcome GPC Biotech AG Investor Relations & Corporate Communications +49 (0)89 8565-2693 ir@gpc-biotech.com or In the U.S.: Laurie Doyle, Director, Investor Relations & Corporate Communications, +1 609-524-5884 usinvestors@gpc-biotech.com or Additional media contacts for Europe: MC Services AG Raimund Gabriel, +49 (0) 89 210 2280 raimund.gabriel@mc-services.eu or Stefan Riedel, +49 (0)...

Word of the Day
  • Good cheer; viands.
  • To revel; to feast.
The word 'bellycheer' may come from 'belle cheer', "good cheer".